Article

The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies

2020-05-10

Abstract excerpt

A new Severe Acute Respiratory Syndrome Coronavirus variant (SARS-CoV-2) that first emerged in late 2019 is responsible for a pandemic of severe respiratory illness. People infected with this highly contagious virus present with clinically inapparent, mild or severe disease. Currently, the presence of the virus in individual patients and at the population level is being monitored by testing symptomatic cases by PC...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 045d169e-4a01-5f84-84fd-dcfec88f6d42
DOI: 10.1101/2020.05.06.20093377

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus AntibodiesDOI 10.1101/2020.05.06.20093377Read

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsSemantic proximity Read

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patientsSemantic proximity Read

Isolation and characterization of neutralizing monoclonal antibodies from a large panel of murine antibodies against RBD of the SARS-CoV-2 Spike proteinSemantic proximity Read

Rapid generation of neutralizing antibody responses in COVID-19 patientsSemantic proximity Read

Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19Semantic proximity Read

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodiesSemantic proximity Read

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1Semantic proximity Read

Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variantsSemantic proximity Read

A comprehensive antigen production and characterization study for easy-to-implement, highly specific and quantitative SARS-CoV-2 antibody assaysSemantic proximity Read

Antibodies and Vaccines Target RBD of SARS-CoV-2Semantic proximity Read

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.Semantic proximity Read

SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patientsSemantic proximity Read